Blog

We took every white-label telehealth platform price we could verify on the vendor's own page on November 4, 2026 and modeled year one at 100, 500 and 1,000 active patients, with setup fees, monthly fees, per-consult fees, merchant fees and ID checks included and every assumption stated. At 1,000 patients the spread runs from about $42,000 (Telegra Plus, before its unpublished consult fee) to $145,000 (Cuvo Grow). Here is the math, what it leaves out, and what to ask the vendors who quote, including us.

Telegra publishes its prices: Plus at $2,999 a month plus $5,000 onboarding, Pro at $5,999 a month plus $10,000, both with a 21-day onboarding timeline. That makes year one about $41,000 or $82,000 before ID checks and medication. Turbopills does not publish a price yet. Here is what each Telegra plan includes, how the ownership questions come out, and when Telegra is the better pick.

Healthie is an EHR and practice platform with a strong GraphQL API, priced from $19 to $149+ a month, and it sits underneath a lot of DTC telehealth brands. Turbopills is the storefront-to-pharmacy platform a brand sells through. Comparing them head to head mostly shows that they do different jobs. Here is which one you need, when you need both, and how they connect.

Bask Health and Turbopills sell the same category of product: storefront, intake, providers, pharmacy and billing under your brand. Bask is the bigger and more self-serve of the two, with 250+ companies on it, a free entry point, and $499 and $3,500 monthly tiers in its own July 2026 plan guide. Here is where the two differ (mobile app, API access, payments, onboarding) and who should pick which.

MD Integrations sells a 50-state, physician-only clinical network that you plug into your own storefront through an API, a white-label intake layer, or its Shopify and WooCommerce integrations. Turbopills sells the whole stack around the clinicians: storefront, intake, billing, pharmacy routing, portal and app. Which one you need depends mostly on whether you already have engineers and a store. Here is the comparison, built only from public facts.

On a white-label platform, a single-state telehealth brand usually sees its first patient 8 to 13 weeks after incorporation and runs paid ads a few weeks later. A custom build takes 5 to 9 months for the same launch. The difference is almost entirely the software track, because the paperwork (entities, licensure, pharmacy, processor, LegitScript) takes the same time on both paths. Here is the week-by-week timeline for each, and which steps can run at the same time.

We read forty Reddit threads posted between April and September 2026 by people launching, running or abandoning telehealth brands, across r/TeleMedicine, r/telehealth, r/nursepractitioner, r/PMHNP, r/MedSpa, r/PaymentProcessing, r/EntrepreneurRideAlong and the patient subreddits they sell to. Six things go wrong, in the same order, in almost every story. Here they are in the founders' own words, with dates, and an honest note on which of them a platform like ours removes and which it cannot.

In 2026 the white-label telehealth category split into a flat-fee lane: Remedora at $200 a month, Karpa from $297, Cuvo at $997 or $2,000 plus $25 a consult, and a handful of others with numbers on their pricing pages. We are the fourth name in this comparison and we do not publish a price yet, so we wrote it with the rules from our other comparisons: only public numbers, plain statements about who each platform is for, and the questions to ask each of us before signing.

Yes, a nurse practitioner can start a telehealth weight loss practice, and in the roughly 28 states with full practice authority the NP can own it outright. The work is in the details that Reddit threads argue about at two in the morning: the collaborating physician who costs 'the most painful $700 a month', the state-by-state licensing, malpractice at $2,400 a year, and the choice between insurance that pays thirty cents on the dollar and cash pay that does not. Here is the whole path, with prices.

If you are shopping for an OpenLoop alternative in September 2026, the honest shortlist has nine names across three lanes, and the differences that matter are not features. They are who publishes a price, who holds the merchant account and the patient relationship, and how many weeks pass before your first patient. Here is the table, the questions the January breach added to every vendor call, and where we fit.

Every platform demo is a performance, and the performance always goes well. This scorecard is how you take control of it: 40 questions across eight areas, each paired with the answer that should worry you, scored live on a 0-1-2 scale. Copy it, send it ahead, and let the reactions do the diligence.

The DEA telehealth flexibilities that let controlled-substance programs prescribe without a prior in-person exam expire December 31, 2026, and the Special Registration rule meant to replace them is still not final. That leaves every ADHD, MAT, testosterone, and controlled-substance mental health program roughly 120 days to plan for three very different endings. This is the contingency plan: the scenario tree, the exposure map, the fallback network, and the decision dates.

In August this post could cite two published prices. On September 22, 2026 we checked every vendor pricing page again and found nine, so it now opens with every published white-label telehealth platform price in one table, from Remedora at $200 a month to Telegra at $5,999 plus $10,000 onboarding, then covers the five pricing models, a worked platform cost at 100, 500 and 2,000 patients, and the nine hidden costs that wreck TCO math.

Every comparison of white-label telehealth platforms is written by a vendor, and this one is too. So we set rules: name who each platform genuinely serves best, say plainly when that is not us, and quote pricing only where a real number is public. Fourteen platforms, one table, every published price checked on September 22, 2026, no scoring theater.

Testosterone prescribing for women is growing faster than almost any corner of hormone care, up nearly 59% year over year by recent prescribing analyses, and it sits almost entirely off-label, which means the clinical governance bar is the product. For operators already serving midlife women, this is the natural deepening of the hormone relationship. For everyone else, it is a masterclass in how labs-first, evidence-honest program design turns a sensitive niche into a durable one. Here is the blueprint.

The half-year funding recap just landed: the strongest first half since 2021, capital concentrating in fewer and larger deals, the busiest acquisition quarter in five years, and AI woven through nearly every major check. Read as a market report, it is interesting. Read as a map of where sophisticated builders are placing bets, it is a strategy memo for every telehealth operator. Here is the operator's read.

You do not need to be a physician to build a telehealth company. The MSO and friendly-PC model is the well-established structure that lets non-clinician founders build, fund, and scale virtual-care brands while licensed clinicians own the medicine. This is the plain-language explainer: what each entity does, how the pieces fit, why the structure exists, and how to set it up so it supports growth instead of slowing it.

Direct-to-consumer telehealth has its own working vocabulary. Some terms are clinical, some are regulatory, some are technical, and some are commercial. A working fluency across all of them is what separates founders who can move quickly from founders who get stuck in vendor conversations. This is the operator's glossary of the 75 terms every DTC telehealth founder, operator, marketer, and clinical lead should know in 2026.

Mid-2026 is the most interesting moment DTC telehealth has had since the pandemic. The compounded GLP-1 era is ending on a hard timeline, branded-access partnerships are the new floor, retail and Big Tech entered the market, EHRs are pivoting to agentic AI, and several adjacent indications became real categories. This is the operator's field report on where the industry is, what changed, and what to build next.

The first 100 patients in a telehealth program are the most valuable feedback loop the brand will ever get. They are the only cohort small enough to know deeply and large enough to draw real patterns from. Used well, they shape every meaningful decision for the next 1,000. This is the founder's playbook for learning from them on purpose.